Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
The original version of this Article contained errors in the author affiliations. Qingnan Zhao, Xueqing Xia, Longfei Huo and Shulin Li were incorrectly associated with Beijing Institute for Brain Disorders, 100069, Beijing, China.This has now been corrected in both the PDF and HTML versions of the A...
Main Authors: | Jun Yan, Qingnan Zhao, Konrad Gabrusiewicz, Ling-Yuan Kong, Xueqing Xia, Jian Wang, Martina Ott, Jingda Xu, R. Eric Davis, Longfei Huo, Ganesh Rao, Shao-Cong Sun, Stephanie S. Watowich, Amy B. Heimberger, Shulin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-02-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-08770-5 |
Similar Items
-
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
by: Jun Yan, et al.
Published: (2019-01-01) -
FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells
by: Qingnan Zhao, et al.
Published: (2023-02-01) -
Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction
by: Somaya A. Abdel-Rahman, et al.
Published: (2023-06-01) -
Targeting FGL2 in glioma immunosuppression and malignant progression
by: Xiaoyu Ma, et al.
Published: (2022-10-01) -
Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1–FGL1–MYH9 axis
by: Xi-Yang Tang, et al.
Published: (2022-10-01)